Filing Details
- Accession Number:
- 0001829126-25-000849
- Form Type:
- 5
- Zero Holdings:
- No
- Publication Time:
- 2025-02-10 18:21:16
- Reporting Period:
- 2024-12-31
- Accepted Time:
- 2025-02-10 18:21:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1527352 | Nexalin Technology Inc. | NXL | Electromedical & Electrotherapeutic Apparatus (3845) | 275566468 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
2053473 | Hamby Carolyn Shelton | 14437 Hidden Loop Road Byhalia MS 38611 | Senior Vp | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-10-14 | 24,000 | $0.85 | 24,000 | No | 5 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 5 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Acquisiton | 2024-11-07 | 90,620 | $0.00 | 90,620 | $0.66 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
90,620 | 2029-09-25 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 24,000 | Direct |
Footnotes
- Represents shares purchased after appointment as Senior Vice President, Quality, Regulatory and Clinical Affairs.
- The reporting person was granted an option to purchase 90,620 shares of common stock. The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending September 16, 2025, 2026 and 2027.